CA2332331A1 - Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance - Google Patents

Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance Download PDF

Info

Publication number
CA2332331A1
CA2332331A1 CA002332331A CA2332331A CA2332331A1 CA 2332331 A1 CA2332331 A1 CA 2332331A1 CA 002332331 A CA002332331 A CA 002332331A CA 2332331 A CA2332331 A CA 2332331A CA 2332331 A1 CA2332331 A1 CA 2332331A1
Authority
CA
Canada
Prior art keywords
egfr
family
radiation
antibodies
receptor tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002332331A
Other languages
English (en)
Inventor
Francisco Robert
Mansoor N. Saleh
Donald Jay Buchsbaum
Harlan W. Waksal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
ImClone LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2332331A1 publication Critical patent/CA2332331A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé servant à inhiber la croissance de tumeurs chez des patients humains, qui comporte l'étape consistant à traiter les patients humains à l'aide d'une quantité efficace de rayonnement combiné à un inhibiteur de tyrosine kinase de récepteurs protéinique non radiomarqué, la surexpression de celle-ci pouvant entraîner la formation de tumeurs.
CA002332331A 1998-05-15 1999-05-14 Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance Abandoned CA2332331A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US60/085,613 1998-05-15
US09/079,612 1998-05-15
US20613898A 1998-12-07 1998-12-07
US09/206,138 1998-12-07
PCT/US1999/010741 WO1999060023A1 (fr) 1998-05-15 1999-05-14 Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance

Publications (1)

Publication Number Publication Date
CA2332331A1 true CA2332331A1 (fr) 1999-11-25

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002332331A Abandoned CA2332331A1 (fr) 1998-05-15 1999-05-14 Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance

Country Status (14)

Country Link
EP (1) EP1080113A4 (fr)
JP (1) JP2002515511A (fr)
KR (1) KR20010071271A (fr)
CN (1) CN1314917A (fr)
AU (1) AU4079999A (fr)
BR (1) BR9910511A (fr)
CA (1) CA2332331A1 (fr)
CZ (1) CZ20004224A3 (fr)
HK (1) HK1040720A1 (fr)
IL (1) IL139707A0 (fr)
MX (1) MXPA00011248A (fr)
PL (1) PL348634A1 (fr)
SK (1) SK17282000A3 (fr)
WO (1) WO1999060023A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (fr) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions et méthodes pour le traitement de tumeurs
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
WO2000074634A2 (fr) 1999-06-03 2000-12-14 Au Jessie L S Methodes et compositions permettant de moduler la proliferation et la mort cellulaire
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
JP2005526506A (ja) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
DE60318561T2 (de) * 2002-04-02 2009-01-08 Nerviano Medical Sciences S.R.L., Nerviano Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005001053A2 (fr) 2003-06-09 2005-01-06 Samuel Waksal Procedes d'inhibition de tyrosine-kinases receptrices au moyen d'un antagoniste extracellulaire et d'un antagoniste intracellulaire
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
EP1694850B1 (fr) 2003-11-12 2011-06-29 Schering Corporation Systeme de plasmide pour l'expression multigenique
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1735348B1 (fr) 2004-03-19 2012-06-20 Imclone LLC Humain anticorps dirige contre le recepteur du facteur de croissance epidermique
AU2005249206A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an EGFR-inhibitor
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2452115T3 (es) 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
WO2007035744A1 (fr) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
EP3770174A1 (fr) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprenant des anticorps spécifiques aux espèces croisées et leurs utilisations
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009001715A (es) 2006-08-21 2009-02-25 Hoffmann La Roche Terapia tumoral con un anticuerpo anti-vegf.
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2009030368A1 (fr) 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Polythérapie avec des anticorps anti-cd20 de type i et de type ii
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (fr) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
JP2013501741A (ja) 2009-08-14 2013-01-17 ロシュ グリクアート アーゲー アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
KR101620661B1 (ko) 2010-04-27 2016-05-12 로슈 글리카트 아게 어푸코실화된 ＣＤ20 항체와 mTOR 억제제의 복합 요법
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
CA2819436A1 (fr) 2010-12-16 2012-06-21 Roche Glycart Ag Therapie d'association d'un anticorps cd20 afucosyle avec un inhibiteur mdm2
WO2012106556A2 (fr) 2011-02-02 2012-08-09 Amgen Inc. Méthodes et compositions associées à l'inhibition d'igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
MX2013011706A (es) 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013071056A2 (fr) 2011-11-11 2013-05-16 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
CN104136464A (zh) * 2012-02-23 2014-11-05 U3制药有限公司 用于调节放射敏感性的her3抑制剂
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
KR102158467B1 (ko) 2012-09-07 2020-09-25 제넨테크, 인크. Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN113607945A (zh) 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
EP3405194A1 (fr) 2016-01-18 2018-11-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Utilisation d'un inhibiteur temporaire de p53 à des fins de prévention ou de réduction des rechutes de cancer
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
EP3658584A1 (fr) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
EP3658188A1 (fr) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Polythérapie faisant appel à un inhibiteur de bet et à un inhibiteur de bcl-2
TW201920282A (zh) * 2017-09-29 2019-06-01 中國大陸商上海藥明生物技術有限公司 抗egfr和pd-1的雙特異性抗體
WO2019201882A1 (fr) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur de bet et un inhibiteur du protéasome
WO2020234445A1 (fr) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2222231A1 (fr) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Also Published As

Publication number Publication date
EP1080113A1 (fr) 2001-03-07
JP2002515511A (ja) 2002-05-28
BR9910511A (pt) 2001-11-20
CN1314917A (zh) 2001-09-26
EP1080113A4 (fr) 2002-04-17
CZ20004224A3 (cs) 2002-02-13
KR20010071271A (ko) 2001-07-28
AU4079999A (en) 1999-12-06
MXPA00011248A (es) 2004-09-06
HK1040720A1 (zh) 2002-06-21
PL348634A1 (en) 2002-06-03
IL139707A0 (en) 2002-02-10
SK17282000A3 (sk) 2002-04-04
WO1999060023A1 (fr) 1999-11-25

Similar Documents

Publication Publication Date Title
US20090297509A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
CA2332331A1 (fr) Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
EP3954712A1 (fr) Anticorps anti-pd-l1/vegf bifonctionnel et son utilisation
KR100269879B1 (ko) 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법
KR101683884B1 (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
US20110274688A1 (en) Prevention of tumors with monoclonal antibodies against neu
US20030202973A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
AU2009255305B2 (en) Monoclonal antibodies to basic fibroblast growth factor
Modjtahedi et al. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor
EP2337800B1 (fr) Combinaisons d'anticorps et utilisation de celles-ci pour traiter le cancer
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
AU2004200705A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
CN114685674B (zh) 一种抗体融合蛋白及其应用
CA2351585A1 (fr) Action de cd66a sur l'angiogenese
KR20060040212A (ko) 표피 성장 인자 수용체에 대한 마우스 단일 클론 항체 및이를 생산하는 하이브리도마

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued